The U.S. Food and Drug Administration approved FAYUVI (rebisufligene etisparvovec-hopf), a gene therapy for Sanfilippo syndrome type A (MPS IIIA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE